|Bid||64.04 x 1300|
|Ask||64.20 x 900|
|Day's range||62.70 - 66.34|
|52-week range||35.25 - 123.99|
|Beta (5Y monthly)||1.75|
|PE ratio (TTM)||N/A|
|Earnings date||27 Apr 2020 - 03 May 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||107.60|
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The growth in genetic testing market can be attributed to factors like rise in incidence of genetic disorders, cancer and technological breakthroughs.
Exact Sciences (EXAS) delivered earnings and revenue surprises of 0.00% and 0.40%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Exact Sciences is the biotech firm behind the popular at-home colon cancer screening test, Cologuard. So is EXAS stock worth considering for growth investors?
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exact Sciences, GameStop, Intel, Intuitive Surgical and Skyworks highlighted as Zacks Bull and Bear of the Day
Robust customer adoption of the HemoSphere all-in-one monitoring platform is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.
Quest Diagnostics' (DGX) acquisition of Clinical Laboratory Services of Boston Clinical Laboratories is expected to have been accretive to its Q4 earnings.
How far off is Exact Sciences Corporation (NASDAQ:EXAS) from its intrinsic value? Using the most recent financial...
Abbott's (ABT) imminent quarterly results are expected to reflect a solid performance by the Established Pharmaceuticals Division (EPD) business alike the last reported quarter.